Bayer files VEGF Trap-Eye for myopic choroidal neovascularization in Japan

German drug major Bayer (BAYN: DE) has submitted VEGF Trap-Eye (aflibercept solution for injection), already marketed under the brand name Eylea, for the treatment of myopic choroidal neovascularization (myopic CNV) for regulatory approval in Japan.

Tatsuro Ishibashi, coordinating investigator of the Phase III MYRROR study, said: “Pathologic myopia, which develops various lesions affecting the back of the eye such as myopic CNV, impacts a significant number of patients in Japan. A treatment option that could not only prevent permanent vision loss but could also improve visual acuity would have great benefits for patients with pathologic myopia.”

Kemal Malik,a member of the Bayer executive committee and head of global development, said: “Unfortunately, mCNV has a poor prognosis and there are more treatment options needed to address this urgent medical need for these patients, many of whom are of working age. We hope to be able to bring VEGF Trap-Eye to patients and the ophthalmology community in Japan soon to improve the prognosis of this vision-threatening condition.”